Literature DB >> 2993405

Metyrapone: an agent for melatonin as well as ACTH and cortisol secretion.

K Brismar, S Werner, M Thorén, L Wetterberg.   

Abstract

The metyrapone-test was used to study the influence of pituitary-adrenal activity on the pineal function in man. We recorded in blood the circadian rhythmicity of melatonin, ACTH and cortisol and the excretion of melatonin, cortisol and Porter-Silber chromogens in urine before, during and after the administration of 750 mg metyrapone every 4 h during 24 h in two healthy volunteers and in two patients with asymptomatic, moderate hyperparathyroidism and a prolactin-secreting microadenoma, respectively. The present study confirmed our previous report on an increased excretion of melatonin per 24 h and per mmol creatinine during the administration of metyrapone. The excretory maximum preceded the maximal ACTH-adrenal response. Serum melatonin remained unchanged during the administration of metyrapone. A second finding was depressed serum melatonin the night after the test in the subjects with the most marked ACTH-cortisol response following the metyrapone-test indicating suppression of melatonin secretion when ACTH-cortisol secretions were increased. A third finding was a late increase in diuresis appearing the day after metyrapone-administration while glomerular filtration rates did not show significant alterations. Thus, it is shown that the metyrapone-induced cortisol inhibition stimulates both ACTH and melatonin secretion, while high ACTH and cortisol levels are accompanied by reduced S-melatonin levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993405     DOI: 10.1007/BF03350653

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma.

Authors:  R H SILBER; C C PORTER
Journal:  J Biol Chem       Date:  1954-10       Impact factor: 5.157

2.  Circadian rhythms in urinary steroids in response to a 36-hour sustained metyrapone administration in eight young men.

Authors:  Y Touitou; A Bogdan; J M Limal; C Touitou; A Reinberg
Journal:  Horm Metab Res       Date:  1977-07       Impact factor: 2.936

Review 3.  Non-reproductive systems and the pineal gland.

Authors:  I Nir
Journal:  J Neural Transm Suppl       Date:  1978

4.  Extra-adrenal actions of metyrapone in man. Effects on plasma cortisol disappearance, growth hormone secretion and glucose metabolism.

Authors:  O D Bruno; R Leclerq; E Virasoro; G Copinschi
Journal:  J Clin Endocrinol Metab       Date:  1971-02       Impact factor: 5.958

5.  Evidence for the existence of a pineal-adrenal and a pineal-thyroid axis.

Authors:  R A DeFronzo; W D Roth
Journal:  Acta Endocrinol (Copenh)       Date:  1972-05

6.  A simplified radioimmunoassay for melatonin and its application to biological fluids. Preliminary observations on the half-life of plasma melatonin in man.

Authors:  L Wetterberg; O Eriksson; Y Friberg; B Vangbo
Journal:  Clin Chim Acta       Date:  1978-06       Impact factor: 3.786

7.  Inhibitory effects of a pineal extract on adrenal cortex. Lack of competition with ACTH.

Authors:  M L Heiman; J R Porter
Journal:  Horm Res       Date:  1980

8.  Radioimmunoassay of melatonin: human serum and cerebrospinal fluid.

Authors:  J Adrendt; L Wetterberg; T Heyden; P C Sizonenko; L Paunier
Journal:  Horm Res       Date:  1977

9.  Extraadrenal effects of metyrapone in man.

Authors:  J Levin; B Zumoff; D K Fukushima
Journal:  J Clin Endocrinol Metab       Date:  1978-10       Impact factor: 5.958

10.  Pineal protein synthesis highly sensitive to ACTH-like neuropeptides.

Authors:  P Schotman; J Allaart; W H Gispen
Journal:  Brain Res       Date:  1981-08-24       Impact factor: 3.252

View more
  2 in total

Review 1.  Sleep and circadian rhythm disorders in fibromyalgia.

Authors:  A Korszun
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.592

2.  Circadian secretion of cortisol and melatonin in cluster headache during active cluster periods and remission.

Authors:  E Waldenlind; S A Gustafsson; K Ekbom; L Wetterberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-02       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.